Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Long-Term Debt Repayments (2024 - 2025)

Puma Biotechnology (PBYI) has disclosed Long-Term Debt Repayments for 2 consecutive years, with $11.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Debt Repayments changed 0.0% year-over-year to $11.1 million, compared with a TTM value of $44.4 million through Dec 2025, up 33.33%, and an annual FY2025 reading of $44.4 million, up 33.33% over the prior year.
  • Long-Term Debt Repayments was $11.1 million for Q4 2025 at Puma Biotechnology, roughly flat from $11.1 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $11.1 million in Q2 2024 and bottomed at $11.1 million in Q2 2024.